MCP
CRL icon

Meridiem Capital Partners’s Charles River Laboratories CRL Stock Holding History

Meridiem Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56M Sell
246,979
-115,119
-32% -$20.5M 2.51% 8
2026
Q1 		$62.5M Buy
362,098
+229,215
+172% +$42.5M 4.07% 3
2025
Q4 		$26.5M Buy
132,883
+62,416
+89% +$11.3M 1.6% 27
2025
Q3 		$11M Sell
70,467
-49,567
-41% -$7.87M 0.7% 48
2025
Q2 		$18.2M Buy
+120,034
New +$16M 1.29% 34

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Meridiem Capital Partners's CRL Position: Q2 2026 in Review

Meridiem Capital Partners reduced its Charles River Laboratories (CRL) stake by 32% in Q2 2026, selling an estimated $20.5M and leaving 246,979 shares worth $56M. The position accounts for 2.51% of the portfolio, ranked #8.

Meridiem Capital Partners first reported a position in CRL in Q2 2025 and has held it in 5 quarters since. The position peaked at $62.5M in Q1 2026. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Meridiem Capital Partners held 246,979 shares of Charles River Laboratories worth $56M as of Q2 2026.
  • Meridiem Capital Partners sold 115,119 Charles River Laboratories shares in Q2 2026, an estimated $20.5M.
  • Charles River Laboratories made up 2.51% of Meridiem Capital Partners's portfolio in Q2 2026, its #8 holding.
  • Meridiem Capital Partners first reported a position in Charles River Laboratories in Q2 2025 and has held it in 5 quarters since.
  • Meridiem Capital Partners's Charles River Laboratories position peaked at $62.5M in Q1 2026.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Meridiem Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.